| Melanomas acquire resistance to B-RAF (V600E) inhibition by RTK or N-RAS upregulation R Nazarian, H Shi, QI Wang, X Kong, RC Koya, H Lee, Z Chen, MK Lee, ... Nature 468 (7326), 973-977, 2010 | 2670 | 2010 |
| RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF (V600E) PI Poulikakos, Y Persaud, M Janakiraman, X Kong, C Ng, G Moriceau, ... Nature 480 (7377), 387-390, 2011 | 1692 | 2011 |
| Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy H Shi, W Hugo, X Kong, A Hong, RC Koya, G Moriceau, T Chodon, R Guo, ... Cancer discovery 4 (1), 80-93, 2014 | 1099 | 2014 |
| Melanoma whole-exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance H Shi, G Moriceau, X Kong, MK Lee, H Lee, RC Koya, C Ng, T Chodon, ... Nature communications 3 (1), 724, 2012 | 841 | 2012 |
| Non-genomic and immune evolution of melanoma acquiring MAPKi resistance W Hugo, H Shi, LU Sun, M Piva, C Song, X Kong, G Moriceau, A Hong, ... Cell 162 (6), 1271-1285, 2015 | 645 | 2015 |
| Therapy-induced tumour secretomes promote resistance and tumour progression AC Obenauf, Y Zou, AL Ji, S Vanharanta, W Shu, H Shi, X Kong, ... Nature 520 (7547), 368-372, 2015 | 516 | 2015 |
| Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours H Yao, J Lan, C Li, H Shi, JP Brosseau, H Wang, H Lu, C Fang, Y Zhang, ... Nature biomedical engineering 3 (4), 306-317, 2019 | 393 | 2019 |
| Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction G Moriceau, W Hugo, A Hong, H Shi, X Kong, CY Clarissa, RC Koya, ... Cancer cell 27 (2), 240-256, 2015 | 392 | 2015 |
| MDM4 is a key therapeutic target in cutaneous melanoma A Gembarska, F Luciani, C Fedele, EA Russell, M Dewaele, S Villar, ... Nature medicine 18 (8), 1239-1247, 2012 | 379 | 2012 |
| Nucleolin is a receptor that mediates antiangiogenic and antitumor activity of endostatin H Shi, Y Huang, H Zhou, X Song, S Yuan, Y Fu, Y Luo Blood, The Journal of the American Society of Hematology 110 (8), 2899-2906, 2007 | 320 | 2007 |
| The regulatory mechanism of Hsp90α secretion and its function in tumor malignancy X Wang, X Song, W Zhuo, Y Fu, H Shi, Y Liang, M Tong, G Chang, Y Luo Proceedings of the National Academy of Sciences 106 (50), 21288-21293, 2009 | 313 | 2009 |
| Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition H Shi, X Kong, A Ribas, RS Lo Cancer research 71 (15), 5067-5074, 2011 | 285 | 2011 |
| Pulmonary vascular destabilization in the premetastatic phase facilitates lung metastasis Y Huang, N Song, Y Ding, S Yuan, X Li, H Cai, H Shi, Y Luo Cancer research 69 (19), 7529-7537, 2009 | 280 | 2009 |
| The angiogenic function of nucleolin is mediated by vascular endothelial growth factor and nonmuscle myosin Y Huang, H Shi, H Zhou, X Song, S Yuan, Y Luo Blood 107 (9), 3564-3571, 2006 | 256 | 2006 |
| HIP1R targets PD-L1 to lysosomal degradation to alter T cell–mediated cytotoxicity H Wang, H Yao, C Li, H Shi, J Lan, Z Li, Y Zhang, L Liang, JY Fang, J Xu Nature chemical biology 15 (1), 42-50, 2019 | 254 | 2019 |
| A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition H Shi, A Hong, X Kong, RC Koya, C Song, G Moriceau, W Hugo, CC Yu, ... Cancer discovery 4 (1), 69-79, 2014 | 194 | 2014 |
| Voltage‐dependent anion channel 1 is involved in endostatin‐induced endothelial cell apoptosis S Yuan, Y Fu, X Wang, H Shi, Y Huang, X Song, L Li, N Song, Y Luo The FASEB Journal 22 (8), 2809-2820, 2008 | 193 | 2008 |
| Immune checkpoint HLA-E: CD94-NKG2A mediates evasion of circulating tumor cells from NK cell surveillance X Liu, J Song, H Zhang, X Liu, F Zuo, Y Zhao, Y Zhao, X Yin, X Guo, X Wu, ... Cancer Cell 41 (2), 272-287. e9, 2023 | 169 | 2023 |
| Artificial intelligence-based multi-omics analysis fuels cancer precision medicine X He, X Liu, F Zuo, H Shi, J Jing Seminars in Cancer Biology 88, 187-200, 2023 | 155 | 2023 |
| Overexpression of platelet-derived growth factor-BB increases tumor pericyte content via stromal-derived factor-1α/CXCR4 axis N Song, Y Huang, H Shi, S Yuan, Y Ding, X Song, Y Fu, Y Luo Cancer research 69 (15), 6057-6064, 2009 | 149 | 2009 |
Roger S. Lo, MD., PhDProfessor of Medicine, Molecular and Medical PharmacologyGeverifieerd e-mailadres voor mednet.ucla.edu